The field of the invention is the extension of a previously implanted lead or electrode to a tissue target.
Neuromodulation devices with a lead to a tissue target still face patient and clinician adoption hurdles. The trial lead is a major effort to demonstrate for a patient the potential result of a permanently implanted device. The trial lead is stimulated by various means, often from outside the body. The prior art trial lead is a temporary lead, often connected to an external pulse generator percutaneously. The trial lead is implanted surgically or otherwise and then removed from the body after a period of days. The patient and clinician then consider the desirability of implanting a permanent lead which would be connected to an implanted internal pulse generator (IPG). If the patient elects to have a permanent lead, a second surgical procedure is required for implanting a second lead at the tissue target. This scenario requires two procedures in which a permanent lead ends up implanted at the tissue target. Disturbing the tissue with a surgical procedure a second time can irritate that tissue and the second procedure also subjects the patient to infection risk. And, of course, the second procedure creates more expense. What is needed is a system and method for implanting at least one lead which can serve as the trial lead for a short period and then remain in place if the patient and clinician so choose: that is, the previously implanted lead can be extended and connected to an IPG.
The present invention enables the clinician to convert a previously implanted trial lead to a permanent lead so that the previously implanted lead can remain in place and be connected to an IPG and be used as a permanent lead for a fully implanted and permanent system. A lead which is well adapted to be the primary lead in the invention herein is the helical wire rope structure electrode is described in PCT/US2021/33007 (PCT '007) and which is fully adopted and incorporated as if set forth entirely herein. PCT '007 does not disclose connecting the primary lead 2 to an IPG 3 or other devices. Additionally, the system can also comprise traditional leads which existed prior to that disclosed in PCT '007.
The invention herein enables the clinician to convert a previously-implanted trial lead to a permanent lead. First, at least one lead 1 has been previously implanted as a trial lead in accordance with the disclosure in PCT '007 and can be powered with an external power source either through a percutaneous tail extending through the skin, or with a transcutaneous connection enabled by a collector just under the skin. If the patient elects for implantation of a permanent system, then the physician makes an incision near the proximal end of the lead, connects the proximal end to another lead or to another device which is outside the scope of this invention. There are numerous methods for these other leads and/or devices to be placed, as approved by regulatory bodies and as performed by clinicians.
Beyond the description of primary lead 2 shown in PCT '007, the lead has a “pin” connector end (elements 7 and 17 in
Each primary lead has its own primary connector on its proximal end. With, say, a socket connector on its proximal end, this primary connector may then be connected to a pin (complementary connector) attached to a lead to one of the following: a commercially available adapter, an IPG, any other type of stimulator, or a helical wire rope structure.
Various embodiments of the system comprise a primary connector which is secured to the proximal end of a primary lead before it is implanted as a trial lead. The primary connector may comprise an internal cavity configured to receive and trap an expanding feature on a dockable connector on a separate secondary lead connected to the IPG, and may also comprise a seal integrated at the entry of the docking cavity to prevent tissue ingrowth and preserve the integrity of the interface.
Each type of indirect connection can be enclosed within a sheath, that is, a sacrificial sleeve, to be pierced or removed prior to placement of the complementary connector which inhibits cellular or fluid entry and maintain a connector for future mating.
The primary lead herein may be connected to a primary connector by an element which is selected from the group consisting of a boa-spring, a loop-through, and/or a direct welded connection to the primary lead or parts thereof to secure the primary lead electrically and mechanically to the indirect connector.
The system 1 herein in
A group of embodiments of the invention establishes a direct connection of a previously implanted primary lead anywhere along its length to a lead to an IPG. A “direct connection” in this usage means no modification of the primary lead is needed. The mechanism for a direct connection is selected from the group consisting of a docking coil assembly, a hook and anvil, and a barracuda clip. Other mechanical connectors within this group may also be used.
Via a “direct connector to socket adapter” extension scheme, a formerly placed lead with no additional modifications can be directly connected in vivo via a needle based procedure, with multiple connector designs described herein (see method 1). The lead can also be modified to include an integrated ‘pin’ connector, with methods and designs of securing the wire structure electrode material to the connectors described herein (see method 2). The ‘socket’ connector is also needle deliverable and extends the wire structure electrode electrical path once connected to the ‘pin’ end and provides an extended end for other devices to be connected to (see method 3).
A zone of innervation can include nerve fibers which are connected to the spinal cord at different vertebra. So, in various embodiments of the invention, the number of leads for interface with the dorsal root ganglion can include two for each vertebra (bilateral) times the number of vertebra where the nerves for that zone attach to the spinal cord for a total of, say, four or six leads.
Delivery methods are conducted either immediately after placement of the electrode (unmodified or modified), or may be conducted at a later time following electrode implant. Devices to achieve the delivery are a series of cannulas with inner diameter larger than that of the cannula deliverable connectors and includes a holding mechanism that temporally secures the target connector in place. The holding mechanism has “soft jaws” that clamp around the target connector and restricts axial movement while the interconnect is formed. Once formed, the holding mechanism releases, with the delivery device retracted to allow full deployment of the “extension” devices described.
It must also be understood that the primary lead 2 and the secondary lead 5 may be separate devices. A first device comprises a primary lead 2 having distal and proximal ends 2a, 2b and a primary connector 4 attached to said proximal end, said device configured for injecting fully into a body through a delivery device, and further configured such that the distal end 2a may be placed near a tissue target and said proximal end 2a is configured to pick up energy from a source internal or external to the body as a trial lead, and said primary connector 4 is available to be connected to a complementary connector 7, which may be connected at the same time as the first device is implanted, or at a later time. A second device comprises at least one secondary lead 5 having first and second ends 5a, 5b, a complementary connector 7 attached to each said first end 5a, and a secondary connector 8 attached to each said second end 5b and configured for connection to an IPG 3 or other device, the complementary connector 7 configured to be connected to a primary connector 4 on a proximal end 2b of a primary lead 2 previously placed in a body.
In another embodiment, the second lead comprises a lead such as a helical wire rope structure with a socket connector.
The system may be placed using the following methods.
Method 1 comprises the steps of (1) placing near a tissue target a primary lead with a primary connector at the proximal end, (2) awaiting tissue ingrowth and testing functionality of the primary lead in a wireless stimulation setup, (3) tunneling to the primary connector end (under fluoroscopy or ultrasound) and forming a secure hold with the delivery system on to the primary connector, (4) placing the secondary lead with a complementary connector into a cannula and establishing interconnection with the primary connector and (5) disengaging the holding mechanism and retracting the delivery cannula to leave behind an extension with an exposed connector end to which additional devices and adapters may then be connected.
Method 2 comprises the steps of (1) placing a primary lead or electrode near a tissue target, (2) awaiting tissue ingrowth and testing its functionality, (3) forming a direct connection (e.g., with a corkscrew connector) to the proximal end of the primary lead using a minimally invasive needle based approach by tunneling to the target (under fluoroscopy or ultrasound), and (4) after placing the direct connector, removing the delivery cannula and connecting an adaptor or implantable stimulation device to be placed in a subcutaneous pocket.
Method 3 comprises the steps of either Method 1 or 2 also immediately after placement of the devices without a period of ingrowth.
Method 4 comprises the steps of Methods 1, 2, or 3, performed in an open cut down, although the minimally invasive cannula based methods are preferable for patient safety and comfort. The placement of an IPG to which the primary lead is connected is performed as an open cut down surgery.
Method 5 comprises the steps of Method 1 or 2 and the additional step of evaluating the usefulness of each of the implanted primary leads and connecting a subset of the implanted primary leads to a secondary lead.
This application claims priority to, and the full benefit of, U.S. provisional patent application No. 63/226,465 filed on Jul. 28, 2021.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US22/38719 | 7/28/2022 | WO |
Number | Date | Country | |
---|---|---|---|
63226465 | Jul 2021 | US |